Mode
Text Size
Log in / Sign up

Clinical Trial Search

Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.

Phase
Intervention
Population
Results posted

30 closest matches · ranked by relevance

Phase 2 N=51 Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression

Metastatic Breast Cancer
Primary: Change From Baseline in Mean Duration of the QTc Interval — 1.2; -1.0; -4.0; -0.1 milliseconds
Genentech, Inc. Results May 2013 12.7% serious AE View details

Phase 1 N=48 Staccato Prochlorperazine Thorough QT/QTc

Cardiotoxicity
Primary: Maximum Effect of Inhaled Prochlorperazine on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo — 5.493; 5.229 milliseconds
Alexza Pharmaceuticals, Inc. Results Mar 2019 0.0% serious AE View details

Phase 1 N=60 CP-690,550 Thorough QTc Study

Healthy
Primary: Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 0.25 Hour Post-Dose — 416.48; 417.77 milliseconds (msec)
Pfizer Results Sep 2020 0.0% serious AE View details

Phase 1 N=60 CiPA Phase 1 ECG Biomarker Validation Study

Drug-induced QT Prolongation · Pharmacokinetics · Pharmacodynamics
Primary: Change From Baseline J-Tpeakc With "Balanced Ion Channel" Drugs (Ranolazine, Verapamil, Lopinavir / Ritonavir) — -8.3; -7.8; -11.5; -10.9 ms
Food and Drug Administration (FDA) Results Jan 2020 0.0% serious AE View details

Phase 1 N=48 Cardiac Safety Evaluation of P03277

Healthy Volunteers
Primary: Change-from-baseline Mean Effect of P03277 on QT Interval Expressed as QTc According to Fridericia's Formula (∆QTcF) — 0.97; 5.05; 0.24; -0.11 milliseconds
Guerbet Results Aug 2019 0.0% serious AE View details